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drugs have become the gold standard treatment for diabetic reti-
nopathy (DR). However, several patients are classified as non-re-
sponders or poor responders to treatment. Therefore, it is essen-
tial to study alternative target molecules. We have previously
shown that the progression of DR in the Ins2Akita mouse reflects
the imbalance between pro- and anti-angiogenic molecules
found in the human retina. We report, for the first time, the
therapeutic potential of a dual-acting antiangiogenic non-viral
gene therapy. We have used an expressing vector encoding
both the pigment epithelium-derived factor gene and a short
hairpin RNA (shRNA) targeted to the placental growth factor
to restore the balance between these factors in the retina.
Twenty-one days after a single subretinal injection, we observed
a marked decrease in the inflammatory response in the neural
retina and in the retinal pigment epithelium, together with
reduced vascular retinal permeability in the treated diabetic
mouse. These results were accompanied by the restoration of
the retinal capillary network and regression of neovasculariza-
tion, with significant improvement of DR hallmarks. Concomi-
tant with the favorable therapeutic effects, this approach did not
affect retinal ganglion cells. Hence our results provide evidence
toward the use of this approach in DR treatment.
INTRODUCTION
It is estimated that 422 million people around the world have been
diagnosed with diabetes.1 Approximately 35% of those with diabetes
have diabetic retinopathy (DR).1 The prevalence of DR increases with
duration of diabetes, and almost all type 1 diabetic patients and 60%
of those with type 2 diabetes have some form of retinopathy 20 years
after the onset of diabetes.2
DR is characterized by progressive damage in the retinal microvascu-
lature caused by the chronic exposure to hyperglycemia. The earliest
clinical signs of DR include thickening of the basement membrane,
loss of pericytes, breakdown of the blood-retinal barrier (BRB), and
appearance of microaneurysms.3–5 As the disease progresses, patients
with pre-proliferative retinopathy display increased intra-retinal
hemorrhages accompanied by cotton-wool spots, indicative of failureMolecular Therap
This is an open access article under the CC BY-NC-in microvascular circulation, resulting in ischemia.4 Later stages of
DR, known as proliferative DR (PDR), are associated with patholog-
ical neovascularization, i.e., the formation of new blood vessels that
develop from the retinal circulation. These new blood vessels can
erupt through the surface of the retina, extend into the vitreous cavity,
and hemorrhage, resulting in blindness.6–8 Besides PDR, a common
cause of vision loss in patients with DR is diabetic macular edema
(DME).9 DME can occur at any stage of DR and cause distortion of
visual images, as well as a decrease in visual acuity. DME is character-
ized by swelling or thickening of the macula caused by the accumula-
tion of intracellular and extracellular fluid within the macular retina,
caused by the breakdown of the BRB.10
Current treatment options for patients with DR are limited. Laser
photocoagulation effectively slows the loss of vision in patients with
PDR, but it does not represent a cure and is in itself a destructive ther-
apy.11,12 Pharmacological inhibition of vascular endothelial growth
factor A (VEGF-A) has shown promising results regarding the pre-
vention of neovascularization.13 However, the therapeutic outcome
is not always satisfactory, with about 30%–50% of DR patients classi-
fied as non-responders or poor responders.14–17 Moreover, persistent
inhibition of VEGF-A may be associated with the risk for formation
of fibrovascular membranes and retinal detachment.18–21 Further-
more, apoptosis of retinal ganglion cells (RGCs) was reported in a pa-
tient with DME undergoing repeated administration of anti-VEGF
treatment for 2 years.22 Additionally, substantial reduction of ama-
crine cell and RGC densities, upon sustained intraocular VEGF-A
neutralization, has been reported in the Ins2Akita diabetic mouse
model23 and in streptozotocin (STZ)-induced diabetic rats.24
Angiogenesis and vascularization are promoted by angiogenic factors,
namely, VEGF family members, which are composed of six secreted
proteins: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, andy: Nucleic Acids Vol. 22 December 2020 ª 2020 The Author(s). 329
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Figure 1. Representation of the Construct for the
Dual-Acting Antiangiogenic Approach
An expression cassette to drive the balance between
angiogenesis mediators was based on a ribozyme archi-
tecture, allowing the encoding of the PEDF gene at the
same time as the production of PlGF shRNA. cis-Acting
ribozymes (50 end hammerhead [HH] and 30 end hepatitis
delta virus [HDV]) were employed to flank nucleotides 50
and 30 of antisense and sense sequences comprising
dsRNAs. Upon expression of the hCMV-driven construct,
the cis-acting ribozymes self-cleave, releasing the PlGF
shRNA.
Molecular Therapy: Nucleic Acidsplacental growth factor (PlGF).25 Although not essential for physio-
logical angiogenesis, PlGF seems to be an important player in patho-
logical angiogenesis.26 Using a mouse model of oxygen-induced
retinopathy (OIR), PlGF-deficient mice demonstrated decreased neo-
vascularization and arterial tortuosity, whereas embryonic angiogen-
esis was not affected.27 Additionally, the ablation of PlGF in a mouse
model of diabetes decreased diabetes-related retinal capillary degen-
eration and pericyte death.28 In accordance with findings from animal
models, studies in DR patients have shown increased PlGF levels in
the retina, vitreous, and aqueous humors.29–34 In fact, the unbalanced
expression levels of pro-angiogenic factors, such as PlGF and VEGF-
A, and angiogenesis inhibitors, such as the pigment epithelium-
derived factor (PEDF), are being pointed out as the leading cause of
neovascularization in DR patients.35,36 PEDF, which is mainly pro-
duced by the retinal pigment epithelium (RPE) in the retina, is a
potent antiangiogenic molecule that counteracts angiogenesis in-
ducers.37 Additionally, PEDF has neuroprotective, anti-inflamma-
tory, and anti-oxidative properties.37,38 The retinal transduction of
PEDF by an adeno-associated virus (AAV) decreased the expression
of angiogenesis-related fibrosis factors, as well as the intraocular levels
of VEGF-A, in transgenic mice overexpressing insulin-like growth
factor-1 (IGF-1) in the retina.39 In fact, management of DR through
gene therapy has been studied in recent years in animal models,
providing confidence that it is an efficient treatment modality. The
therapeutic effects of viral- and non-viral-mediated expression of
neuroprotective, anti-apoptotic, and antiangiogenic molecules in
the retina have shown promising results.40 Previous studies from
our group have reported the effectiveness of a self-replicating
episomal vector, pEPito, in the long-term gene expression in the
mouse retina.41,42 Based on that, in this study, we further addressed330 Molecular Therapy: Nucleic Acids Vol. 22 December 2020the therapeutic potential of a dual-acting antian-
giogenic gene therapy, in the retina of a mouse
model of type 1 diabetes, Ins2Akita mice, using
the pEPito expressing system (Figure 1). This ex-
pressing vector encoded both PEDF transgene
and a short hairpin RNA (shRNA) targeting the
PlGF gene (pPEDF-shPlGF) with the aim of
restoring the balance between both factors, which
is deeply impaired in diabetic Ins2Akita mouse
retina with disease progression, as we previously
reported.43 The rationale behind this combina-tory treatment was based on the well-established role of PlGF in
DR pathology, on the strong antiangiogenic action of PEDF in the
retina, and on the inverse correlation observed in their expression
levels in DR conditions. For the first time, the rescue of the equilib-
rium between an angiogenesis inducer and an angiogenesis inhibitor,
using a non-viral vector, was studied as a potential therapeutic strat-
egy for DR.
RESULTS
The Administration of the Anti-angiogenic Dual-Acting Therapy
Did Not Induce Adverse Reactions
The animals injected subretinally with the therapy were followed
for 21 days post-administration. No changes in grooming, behavior,
or food or water consumption were observed. Additionally, visual
inspection of the eyes of animals within the experimental groups
revealed no signs of ocular inflammation or changes in overall
health status.
The Balance between Angiogenesis Inducers and Inhibitors Is
Restored in RPE and Neural Retina with the Administration of
pPEDF-shPlGF
We have previously shown that similarly to DR patients, the progres-
sion of the disease in the Ins2Akita mouse model reflects the imbalance
in the expression of pro- and anti-angiogenic factors in the neural
retina and RPE.43 Therefore, to explore whether our dual-acting
anti-angiogenic strategy would be effective in restoring the equilib-
rium between PEDF and PlGF in vivo, we have analyzed the protein
levels of angiogenic factors in animals injected with the control
(empty vector) or with pPEDF-shPlGF, 21 days following subretinal
injection. We have observed a marked increase in PEDF expression,
Figure 2. Expression of Diabetic Retinopathy-Associated Molecules in the Neural Retina and the RPE of Ins2Akita Mice 21 Days after Subretinal Injection of
the Empty Vector or pPEDF-shPlGF
(A–H) Quantification of protein levels of the (A and C) angiogenesis inhibitor PEDF, of the pro-angiogenic factors (B and D) PlGF and (F and H) VEGF-A, and the pro-in-
flammatory cytokine (E and G) IL-1b, in the neural retina and in the RPE layer. (I and J) Representative western blot data for the studied key molecules in the neural retina and
RPE. Protein levels were normalized to b-Actin, followed by a ratio between the expression of the correspondent protein in the injected eye (I) over the non-injected (NI) one.
Data are expressed as mean ± SEM (n = 4 mice/group). *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test.
www.moleculartherapy.orgby approximately 50%, in the neural retina following administration
of the dual-acting anti-angiogenic strategy (Figure 2A) and a signifi-
cant reduction in PlGF expression by approximately 40% (Figure 2B)
when compared with the control group. Similarly, in the RPE, we
have detected a significant increase in PEDF levels (mean increase
of 39%; Figure 2C) and a significant decrease in PlGF (mean decrease
of 34%; Figure 2D) upon comparison with the control group.
We have also analyzed the protein levels of VEGF-A, a major angio-
genesis inducer overexpressed in DR conditions and deeply involved
in the development of vascular permeability and pathological neovas-
cularization.44 The results show a significant decrease in VEGF-A inthe neural retina when compared with the control group (Figure 2E),
but no significant changes were detected in the RPE layer (Figure 2G).
Several inflammatory cytokines have been shown to be critical to the
development of DR. Interleukin-1b (IL-1b), among others, has been
found in high concentrations in the vitreous of DR patients.45,46
Therefore, we have assessed the protein levels of this pro-inflamma-
tory cytokine in the neural retina and the RPE of diabetic mice in-
jected with pPEDF-shPlGF or control. As shown in Figure 2F, there
is a significant decrease of almost 50% in IL-1b in the neural retina
and approximately 40% in the RPE layer of the pPEDF-shPlGF-in-
jected animals, when compared with the control group.Molecular Therapy: Nucleic Acids Vol. 22 December 2020 331
Figure 3. Microglia Activity in the Retina of Non-
diabetic and Diabetic Mice 21 Days after Subretinal
Injection of the Empty Vector or pPEDF-shPlGF
(A) Iba1 (microglia/macrophage marker) immunolabeling
(red) of Ins2Akita retinal sections. DAPI (blue) stains nuclei.
Scale bar: 50 mm. (B) Quantification of Iba1 protein
expression levels in the retina and representative western
blot data for Iba1. Protein levels were normalized to
b-actin, followed by a ratio between the expression of the
correspondent protein in the injected (I) eye over the NI
one. Data are expressed as mean ± SEM (n = 4 mice/
group). ***p < 0.001, Student’s t test. Scale bars: 50 mm.
GCL, ganglion cell layer; INL, inner nuclear layer; ONL,
outer nuclear layer.
Molecular Therapy: Nucleic AcidspPEDF-shPlGF Injection Reduces Microglia Activity
The increase in the expression of cytokines observed in DR potenti-
ates microglia activation, which in turn results in its proliferation
and migration, causing tissue damage.47 To analyze microglial activ-
ity, we sacrificed animals 21 days post-injection and sectioned their
retinas for immunohistochemical analysis. As evidenced in Figure 3A,
the analysis of the immunolabeling of the microglia/macrophage
marker, ionized calcium-binding adaptor molecule 1 (Iba1), in retinal
sections shows an increase in the density of microglia in diabetic mice
when compared with non-diabetic animals (wild-type [WT] ani-
mals). Following the injection of pPEDF-shPlGF in diabetic animals,
we have observed a marked decrease in the microglia labeling, similar
to non-diabetic mice, when compared with control groups. Further-
more, we also verified a decrease in the number of vertically oriented
processes that represents the microglia infiltration on multiple retinal
layers, compared with non-injected and control-injected groups (Fig-
ure 3A). These results suggest that activation of the microglia
observed in untreated diabetic animals is reduced in treated animals.
In agreement with the immunohistochemistry results, we have found
a significant decrease in Iba1 protein levels (mean decrease of 58%) in
pPEDF-shPlGF-injected retinas, compared with the control group, as
assessed by western blot (Figure 3B).
Vascular Leakage Is Decreased upon pPEDF-shPlGF
Administration
The breakdown of the BRB is an early sign of DR, which further re-
sults in vascular leakage.4 Mouse perfusion with the Evans blue dye
is an efficient method to observe retinal blood vascular leakage,48
and it was used to assess the impact of pPEDF-shPlGF therapy on
this DR hallmark. In non-diabetic retinas, almost all Evans blue dye
remained within the intact blood vessels, which contrasts with the
non-injected or empty vector-injected diabetic retinas of Ins2Akita
mice, where a pronounced leakage of the dye was observed for both332 Molecular Therapy: Nucleic Acids Vol. 22 December 2020capillaries and larger-caliber vessels (Figures
4A and 4B). In contrast, the vascular perme-
ability was remarkedly decreased in pPEDF-
shPlGF-treated retinas, with a visible reduction
of dye extravasation from the vessels, comparedwith control groups, as observed in the whole-mount images
(Figure 4A).
pPEDF-shPlGF Restores the Vascular Network
To analyze the vascular organization, we labeled whole-mount retinas
of WT, treated, and non-treated diabetic mice with Isolectin B4 (Fig-
ure 5). The vasculature from non-diabetic (WT) animals shows
normal vessel structure, as well as a uniformly distributed capillary
network (Figure 5A). As predicted, the diabetic non-injected and
the empty vector-injected retinas revealed abnormal and disorganized
vasculature, with points of vessel dilation and vessel attenuation (Fig-
ures 5A and 5B). By contrast, the pPEDF-shPlGF-injected diabetic
retinas displayed a solid capillary network, with retinal vessels radi-
ating from well-defined optic nerve heads (Figure 5B). To obtain a
measure of the retinal vascularity in all tested conditions, we have
quantified eight images of the deep vascular plexus (Figure 5C),
captured in the four quadrants, of each of the experimental condi-
tions, which were processed using the AngioTool software. Retinas
from non-injected and empty vector-injected diabetic mice exhibited
a significant increase in deep vascular density, as demonstrated by the
increase in total vascular area, vessel length, and number of junctions,
as well as a decrease in lacunarity, when compared with non-diabetic
mice (Figures 5D–5G). In striking contrast, the vascular status of
pPEDF-shPlGF-injected retinas was similar to the non-diabetic
group, with similar values in total vascular area, vessel length, number
of junctions, and lacunarity. Moreover, the number of junctions was
significantly decreased in pPEDF-shPlGF-injected retinas compared
with both diabetic control groups (Figure 5G).
pPEDF-shPlGF Does Not Affect RGCs’ Density
Neuronal loss, in particular of RGCs, is a consequence of the diabetic
condition, which is mainly caused by neuroinflammation and micro-
glia activation.47 In order to analyze the RGCs’ density in mice retinas
after treatment, 21 days post-administration we have labeled retinal
Figure 4. Retinal Vascular Permeability in the Retina
of Non-diabetic and Diabetic Mice 21 Days after
Subretinal Injection of the Empty Vector or pPEDF-
shPlGF
(A) Representative images of Evans blue retinal fluores-
cence in vessels of whole-mount retinas of non-diabetic
and diabetic mice. Each retinal flat mount was stitched
from 64 images acquired with 20 objective. (B) Magnified
images of areas of vascular leakage at specific points of
the vessels. (C) Quantification of the vascular permeability
(the dataset was graded in a scale of 1 to 5, depending on
the severity of the Evans blue leakage, by a masked
investigator). n = 5 mice/group. Scale bars indicate
400 mm (A) or 50 mm (B).
www.moleculartherapy.orgsections with anti-gamma synuclein, as previously described.49 RGCs
counts were significantly higher in non-diabetic mice (28 ± 1/200 mm
retinal length) when compared with diabetic retinas (22.8 ± 0.11/
200 mm retinal length) (Figure 6). Our results show that RGCs counts
of pPEDF-shPlGF-injected retinas (22.6 ± 1/200 mm retinal length)
were not significantly different from non-injected (22.9 ± 0.12
/200 mm retinal length) and control-injected retinas (23 ± 1.5/
200 mm retinal length) (Figure 6).
DISCUSSION
With the growing burden of diabetes over the last few decades, the
incidence of DR has been steadily increasing. Furthermore, as the
average life expectancy increases and with the duration of diabetes
being the strongest predictor for development and progression of reti-
nopathy, it is crucial to find effective therapies to treat chronic ocular
pathologies for longer periods of time.
Currently, the gold standard in clinical practice for DR is the intravi-
treal injection of neutralizing antibodies against VEGF-A, which de-
creases vascular lesion and improves visual acuity after repeated injec-
tions.50–52 Although VEGF-A is an essential contributor to the
pathogenesis of DR, it is also essential for neuronal function and sur-
vival,53 with reported neuronal loss of bipolar and amacrine cells
upon sustained depletion of VEGF-A, in a diabetic rat model.24
Therefore, it is essential to find therapeutic alternatives able to restore
the vascular network and, at the same time, preserve the neuronalMolecular Theracells. In this regard, gene therapy offers the pos-
sibility of a long-term, sustained, and fine-tuned
therapeutic.
We have recently described that the expression
of pro- and anti-angiogenic factors is dysregu-
lated in the retina of the Ins2Akita mouse
model.43 Specifically, we have observed
increased levels of PlGF and decreased levels of
PEDF, concomitant with disease progression,
contributing to features of both early and late
stages of DR.43 Although the Ins2Akita mouse
does not present the severe phenotype seen inadvanced stages of DR in human patients, in the present study we
have confirmed that there is, in fact, the development of vascular
leakage and neovascularization in the deep plexus at 11 months of
age. These results are in accordance with studies performed in 9-
and 10.5-month-old animals.54,55 Therefore, in this work, we aimed
to restore the retinal network physiopathology by restoring the bal-
ance between players of angiogenesis, through the upregulation of
PEDF and silencing of PlGF. The potent anti-angiogenic action of
PEDF in combination with its anti-inflammatory and neuroprotec-
tive effects has been shown to have protective effects against retinal
cell death.56 In contrast with PEDF, PlGF is considered not only an
inducer of angiogenesis but also a modulator of inflammation associ-
ated with pathological angiogenesis. PlGF promotes inflammation by
recruiting and activating macrophages via VEGFR-1 signaling,
inducing the secretion of pro-inflammatory cytokines.57,58 Therefore,
PlGF has a preponderant role in the context of inflammation,
compared with VEGF-A. In fact, a study conducted by Van Bergen
et al.59 demonstrated that PlGF neutralization showed comparable ef-
ficacy as anti-VEGF therapy regarding vascular permeability; howev-
er, whereas PlGF inhibition reduced inflammation, anti-VEGF ther-
apy did not have an effect on the inflammatory response. Therefore,
PlGF inhibition combined with PEDF overexpression could poten-
tially offer additional benefit in the inflammatory context compared
with anti-VEGF treatment, which could be of relevance especially
in patients with DME. In fact, in all studied models of pathological
angiogenesis, the deletion of PlGF impaired the associatedpy: Nucleic Acids Vol. 22 December 2020 333
Figure 5. Isolectin-GS IB4Staining of Retinal FlatMounts of Non-diabetic andDiabeticMice 21Days after Subretinal Injection of the Empty Vector or pPEDF-
shPlGF
(A) Representative images of whole-mount retinas of non-diabetic or diabetic retina. Each retinal flat mount was stitched from 64 images acquired with the 20 objective
using a confocal microscope. (B) Magnified image of the central area of the optic disk. (C) Representative confocal images of the retina deep plexus (original magnification
40). (D–G) Images of the indexes of vascularity: (D) vascular area, (E) vessel length, (F) lacunarity, and (G) number of junctions. Data are expressed as mean ± SEM (n = 5
mice/group) analyzed by one-way ANOVA followed by Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, compared with control. Scale bars indicate
400 mm (A), 150 mm (B), and 50 mm (C). ND, non-diabetic; ns, not statistically significant.
Molecular Therapy: Nucleic Acidsinflammation and angiogenesis.27 Moreover, a preclinical study re-
vealed that the injection of an antibody against PlGF in three different
mouse models, STZ-diabetic, Akimba, and the non-diabetic laser-
induced choroidal neovascularization model, reduced inflammation
and vascular leakage.59 The transition from animal to human studies
was already done, between 2017 and 2019, in the form of two phase II
clinical trials to assess the therapeutic potential of an anti-PlGF re-
combinant monoclonal antibody in DR/DME patients, which
demonstrated safety and efficacy (ClinicalTrials.gov: NCT03071068334 Molecular Therapy: Nucleic Acids Vol. 22 December 2020and NCT03499223; ThromboGenics). We have recently described
the enhanced antiangiogenic effect of PEDF overexpression in com-
bination with PlGF silencing compared with single approaches, in
RPE cells, in vitro.60
Herein, we have observed that a single subretinal injection of pPEDF-
shPlGF significantly increased the protein levels of PEDF and
decreased the expression of PlGF in both the neural retina and
RPE. Additionally, we have observed a significant decrease in the
Figure 6. Retinal Ganglion Cells’ Density in Retinal
Sections of Non-diabetic or Diabetic Mice, 21 Days
after Subretinal Injection of Empty Vector or pPEDF-
shPlGF
(A) Representative images of the RGC marker gamma-
synuclein in control and treatment retinas and (B) quantifi-
cation of RGC counts over a 200-mm retinal length. Data
are expressed as mean ± SEM (n = 4 mice/group) analyzed
by one-way ANOVA followed by Tukey’s multiple com-
parisons test. *p < 0.05. Scale bar indicates 50 mm.
www.moleculartherapy.orglevels of the pro-inflammatory and pro-angiogenic molecules VEGF-
A and IL-1b. Previous reports correlate increased levels of VEGF-A
and IL-1b with a pathological increase of vascular permeability.61,62
Our results are supported by these findings, because we have
observed, upon treatment of diabetic mice with pPEDF-shPlGF,
decreased levels of these cytokines along with the decrease in retinal
vascular permeability, as shown by the decrease of Evans blue vessels
extravasation. Although we did not study directly the impact of our
strategy in DME pathology, the decrease in the vascular permeability,
observed after treatment, suggests that this approach could benefit pa-
tients with this devastating condition. In fact, increased levels of
PlGF33 and decreased levels of PEDF29 have been reported in patients
with DME. Moreover, it was described that the injection of PlGF into
rat eye vitreous resulted in the impairment of RPE tight junctions and
subsequent subretinal fluid accumulation, suggesting that PlGF could
be a key target for the control of DME.63
We have also detected increased microglia activity in 11-month-
old animals, correlated with previous observations in 6-month-old
Ins2Akita mice,64 thus suggesting that the pro-inflammatory state per-
sists with the chronic exposure to hyperglycemia, contributing to
vascular permeability and neuronal apoptosis. Nevertheless, we
have observed reduced Iba1 levels by immunofluorescence and
immunoblotting, upon pPEDF-shPlGF injection, which indicates
reduced microglial activity. Additionally, it is visible in diabetic con-
trol retinas that some microglia cells migrated or extended their pro-
cesses to the photoreceptor layer (outer nuclear layer), which is not
observed in treated retinas. This observation is consistent with the
hypothesis that photoreceptors are also negatively impacted in DR.
Unlike previous studies reporting the absence of neovascularization
in the Ins2Akita mouse, following 6 months of hyperglycemia,65 we
have observed an increase in total vessel length and area in the
deep vascular plexus of diabetic animals, as well as an increase in
number of junctions and a decrease in lacunarity when compared
with non-diabetic mice. These results are similar to those described
by Carroll et al.54 in a study with 10.5-month-old Ins2Akita mice.
The contradictory results could be because of the discrepancy inMolecular Therathe age of the animals analyzed, because most re-
ports do not go beyond 6 months of hyperglyce-
mia, the time at which the first signs of vascular
damage are visible.64,66 In fact, the describedcapillary loss and deep retinal ischemia in Ins2Akita mice at 6 months
might give rise to vascular remodeling to restore blood flow, as
observed in older animals in later stages of the disease.
Because DR patients typically present no symptoms during the early
stages of the disease, the condition is often at an advanced stage when
detected, so the development of therapeutic strategies that are effec-
tive in the proliferative stages of the disease is crucial. Upon treatment
with pPEDF-shPlGF, we here demonstrate a notable regression of
neovascularization in 11-month-old proliferative Ins2Akita retinas.
In fact, there was a visible improvement in the retinal vasculature
network in treated animals, displaying solid, functional blood vessels
radiating from the center of the optic nerve.
Along with the favorable therapeutic effects on vascular permeability
and neovascularization of pPEDF-shPlGF, we did not observe any
impact on RGC density, when compared with diabetic animals.
This result suggests that this strategy does not trigger a neurodegen-
erative response. Nevertheless, we observed a decrease in RGC density
in diabetic animals, in accordance with a previous report.65 Although
future studies in younger animals are essential, we hypothesize that it
could be possible to delay the progression of the disease even before
the proliferative phase. Neurodegeneration and inflammation are
early events in DR. Considering that there is some evidence on the
neuroprotective effect of PlGF inhibition28,67 and given the well-es-
tablished role of PEDF on retinal protection, we could predict that
treatment administration in early stages of DR could retard the
neurodegenerative process, preserving the retinal tissue. Moreover,
given the anti-inflammatory properties of PEDF and the inflamma-
tory action of PlGF, the studied approach, by overexpressing PEDF
and silencing PlGF, could represent a beneficial treatment for patients
diagnosed in earlier stages, without the need of frequent injections
typical of conventional treatments.
As already described by our group, the pEPito vector is less affected
by epigenetic silencing and consequently is able to promote sus-
tained gene expression in the retina for at least 3 months.42 Specifically,
pEPito vector contains a scaffold/matrix attachment region (S/MAR)py: Nucleic Acids Vol. 22 December 2020 335
Molecular Therapy: Nucleic Acidsderived from the human interferon b-gene, enabling its replication and
co-segregation with the chromosomes upon mitosis. Additionally, it
was shown that the S/MAR-containing vectors prevent epigenetic
silencing of gene expression by shielding the transgene sequence
from adjacent regulatory sequences and heterochromatinization,main-
taining the vector in a transcriptionally active state. Furthermore, pE-
Pito vector was constructed by cloning the pEPI-1 plasmid replicon
in a plasmid backbone containing 60% less CpG motifs, and so is
less affected by epigenetic silencing events.68 Therefore, the success
of this dual-acting approach in rescuing the balance between PEDF
and PlGF has potential for a long-term therapeutic effect.
The majority of studies describing therapeutic approaches for DR
focused on a single gene, targeting a specific pathological change
over a relatively short time frame, which is not adequate to the complex
pathophysiology of DR. The strategy described in this work combines
the potential of gene therapy in long-term therapeutic action, with the
dual modulation of genes deeply involved in DR progression. There-
fore, this strategy could represent an innovative and effective therapy
not only for DR but possibly for other retinal neovascular diseases.
MATERIALS AND METHODS
Design of the Anti-angiogenic Dual-Acting Vector
To simultaneously express PEDF and PlGF shRNA, we have used a
combination of the polymerase II promoter (human cytomegalovirus
[hCMV] enhancer/human elongation factor 1 alpha promoter) in
conjunction with cis-acting ribozymes. cis-acting ribozymes (50 end
hammerhead [HH] and 30 end hepatitis delta virus [HDV]) were em-
ployed to cleave nucleotides 50 and 30 of antisense and sense sequences
comprising double-stranded RNAs (dsRNAs). Upon expression of
the hCMV-driven construct, the cis-acting ribozymes self-cleave,
releasing the shRNA to produce functional small interfering RNAs
(siRNAs) to suppress the PlGF gene (Figure 1).
Animal Husbandry
The type 1 diabetic Ins2Akita mouse with a C57BL/6J background was
used to model DR. This animal harbors a point mutation in the Insu-
lin 2 gene that prevents proper insulin secretion leading to pancreatic
b cell toxicity.69,70
The Ins2Akita heterozygous male and female breeder pairs (Jackson
Laboratory, USA) were maintained and handled in accordance with
the Portuguese and European Laboratory Animal Science Association
(FELASA) Guide for the Care and Use of Laboratory Animals, the Eu-
ropean Union Council Directive 2010/63/EU for the use of animals in
research, and the Association for Research in Vision and Ophthal-
mology (ARVO) for the use of animals in ophthalmic and vision
research. Animal experiments have been performed under the approval
of the Portuguese national bodyDGAV (Direção Geral de Alimentação
e Veterinária) and the institutional Ethics Review Board (CEFCM).
Animals were housed in a pathogen-free environment, with
controlled temperature and a 12-h light/dark cycle with food and wa-
ter ad libitum.336 Molecular Therapy: Nucleic Acids Vol. 22 December 2020Only heterozygous male mice were included in this study, because
mice homozygous for Ins2Akita mutant allele exhibit post-natal
lethality, and disease progression in females is slower and less uni-
form than in males.70 The diabetic phenotype was confirmed
2 months after birth from a tail puncture with blood glucose levels
higher than 250 mg/dL (Contour TS Blood Glucose Meter; Bayer,
Germany).
Vector Construction
The pEPito-hCMV-EGFP plasmid containing the human CMV
enhancer/human elongation factor 1 alpha promoter was used as back-
bone.41 The sequence PEDF-HH-PlGFshRNA-HDV, flanked by Nhe I
(50) and Acc III (30) restriction sites (synthetized by Genecust, France),
was digested with Nhe I and Acc III restriction enzymes and subcloned
into the pEPito-hCMV backbone. The resulting construct was
confirmed by restriction pattern and Sanger sequencing.
Subretinal Injection
Ins2Akita mice were randomly assigned to an experimental treatment
group: pEPito-hCMV (reporter) or pEPito-hCMV-PEDF-shPlGF
(pPEDF-shPlGF). WT littermates did not receive any treatment.
Ten-month-old Ins2Akita mice were injected with 1 mL of reporter
plasmid or pPEDF-shPlGF into the subretinal space (1 mg/mL), with
the contralateral eye used as non-injected control. Subretinal injec-
tions were performed in animals anesthetized by intraperitoneal
(i.p.) injection of Avertin, and pupils dilated by using 1% tropicamide.
A 30G needle was used to puncture a hole approximately 1 mm below
the limbus, followed by the use of an automatic pump injector (WPI)
to inject either treatment. The injected eye was then electroporated
using 7-mm tweezer electrodes (Tweezertodes; Harvard Apparatus,
USA) connected to a BTX ECM 830 (Harvard Apparatus), as previ-
ously described.71
Western Blot Analysis
Twenty-one days post-injection, the animals were humanely sacri-
ficed by cervical dislocation, and the eyes were enucleated. The neural
retina and the RPE were isolated by dissection of the eyeball. The tis-
sue was homogenized in ice-cold radioimmunoprecipitation assay
(RIPA) buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40 [NP-
40], 0.25% Na-deoxycholate, 150 mM NaCl, and 1 mM EDTA) con-
taining a protease inhibitor cocktail (Roche, Germany). The cell ly-
sates were then centrifuged at 13,000 rpm for 20min at 4C to remove
cellular debris.
Protein content was determined by the Bradford assay, using the Dye
Reagent Concentrate assay (Bio-Rad, UK) and bovine serum albumin
(BSA) (Nzytech, Portugal) as a standard curve. A total of 30 mg of pro-
tein was separated by a SDS-PAGE gel, transferred to a nitrocellulose
membrane (GE Healthcare, UK), and blocked in 5% BSA in Tris-
buffer saline (20 mM Tris base, 150 mM NaCl, pH 7.6) with 0.1%
Tween 20 (TBS-T) (Sigma-Aldrich, USA) for 1 h at room tempera-
ture. The following primary antibodies were incubated overnight at
4C: rabbit polyclonal anti-PEDF (1:500; Millipore, USA), rabbit
polyclonal anti-VEGF-A (1:500; Abcam, UK), rabbit polyclonal
www.moleculartherapy.organti-PlGF (1:500; Abcam), goat polyclonal anti-Iba1 (1:500; Sigma-
Aldrich), and rabbit polyclonal anti-IL-1b (1:1,000; Abcam). b-Actin,
used as a control, was incubated for 1 h at room temperature
(1:10,000; Sigma-Aldrich). The membrane was probed with horse-
radish peroxidase (HRP)-conjugated secondary antibodies (Santa
Cruz Biotechnology) in a 1:5,000 dilution for 1 h at room tempera-
ture. The immunoreactive bands were detected by chemilumines-
cence, using the ECL Blotting Reagent (GE Healthcare, UK).
Immunofluorescent Labeling of Retinal Cryosections
To evaluate the effect of our therapeutic approach on retinal inflam-
mation in the Ins2Akita mouse model of DR, we evaluated the number
of microglia cells andmacrophages in the diabetic retina 21 days post-
injection. In brief, the eyes were fixed in ice-cold 4% paraformalde-
hyde (PFA) in PBS overnight at 4C. Afterward, the eyes were cryo-
protected in a gradient of 10%–30% sucrose in PBS (1 h in sucrose
10%, 1 h in sucrose 20%, and overnight in sucrose 30%) and then
embedded in OCT mounting medium (Tissue-Tek). Serial sections
of 10 mm were blocked in 1% goat serum/PBS at room temperature
for 1 h. Primary antibodies, mouse anti-Iba1 (1:500; Wako, USA)
and rabbit anti-gamma synuclein (1:500; Abcam, USA), were incu-
bated overnight at 4C. Samples were washed three times in 0.1%
Triton X-100/PBS and incubated with respective secondary anti-
bodies (Alexa Fluor 488 and 594; 1:500; Life Technologies, USA)
for 1 h at room temperature. Slides were washed three times and
were mounted with Fluoromount G (Southern Biotech, USA) con-
taining 4’,6’-diamidino-2-phenylindole (DAPI). Images were ac-
quired using a Zeiss 710 confocal microscope, using appropriate filter
sets (LSM 710; Carl Zeiss, Germany).
Retinal Vascular Leakage Assay
Retinal vascular leakage was evaluated using the Evans blue assay, as
previously described.48 Twenty-one days after subretinal injection,
anesthetized mice were administered Evans blue (2% in PBS) by i.p.
injection, with visual confirmation of the uptake and distribution of
the dye. Two hours later, mice were sacrificed by cervical dislocation;
the eyes were removed and immediately immersed on 4% PFA. After
2 h, the retinas were carefully dissected and flat mounted in glass
slides. Retinal flat mounts were analyzed under a confocal microscope
(LSM 710; Carl Zeiss, Germany) to visualize retinal vessel leakage.
Immunofluorescent Labeling of Retinal Flat Mounts
For flat-mount preparation, mice were sacrificed 21 days post-injec-
tion, and retinas were carefully dissected from enucleated ocular
globes and fixed in 4% PFA/PBS overnight at 4C. After washing in
1 PBS, retinas were permeabilized in 1% Triton in 1 PBS for 2 h
at room temperature and then blocked in 10% goat serum, 1% BSA
in 1 PBS overnight at 4C. Retinas were incubated with Griffonia
simplicifolia Lectin I, Isolectin B4 (Sigma-Aldrich, USA) diluted in
blocking buffer to a final concentration of 1:200 and incubated for
3 days at 4C. Samples were washed, incubated with streptavidin
(1:100; Vector Laboratories, UK), and then incubated with fluorescein
(1:80; Perkin Elmer, USA) at room temperature, according to the
manufacturers’ instructions. After the final washing steps, retinaswere flattened with four equidistant incisions toward the optic disk
and mounted with Fluoromount G (Southern Biotech, USA). All sec-
tions were viewed and imaged using a Zeiss 710 confocal microscope,
with appropriate filter sets (LSM 710; Carl Zeiss, Germany) at 40
magnification. Eight images per retina were acquired (two images
in each quadrant). The eight values representing eight separate pe-
ripheral retinal fields were averaged for each eye. Described statistics
are for total length of vessels, lacunarity (an index of “gappiness”
within the image), number of vessel junctions, and area of vessels,
processed through the AngioTool Software.72
Image Analysis
All images were analyzed using ImageJ software (Fiji image process-
ing package). Two-dimensional (2D) images of each retinal flat
mount were reconstructed from z stacks. For retinal vascular leakage
analysis and Isolectin B4 staining, a composite picture of the whole
retina vasculature was obtained by overlapping confocal images
(20 lens) in a tile scan of an 8  8 grid, for a total of 64 images.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software.
The Student’s t test with a significance level of 0.05 was used to
compare differences between two groups. One-way ANOVA was
used to analyze differences between treatment groups and was fol-
lowed by Tukey’s honest significant difference (HSD) test for pairwise
comparisons. Differences were considered statistically significant at
p < 0.05 in all experiments: *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. All data are expressed as mean ± standard error of
the mean (SEM).
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